How do we figure out the “optimal dose” of a NOAC for our patients?
Transatlantic Dialogues on Controversies in Contemporary Cardiology 2016, Rome
When do we dose differently from the recommendations in the “package insert”? Why do we often “underdose” NOACs?Aug. 28, 2016 - Rome, Italy - Samuel Z Goldhaber, MD – Boston, MA, USA
As part of a shared session at the Brigham and Women's Hospital and PACE-cme Transatlantic Dialogue, Samuel Z Goldhaber considered the balance between the effect of NOACs on efficacy in preventing stroke and the risk of bleeding. How can NOACs best be dosed for an optimal balance?
Brigham and Women’s Transatlantic Dialogues on Controversies in Contemporary Cardiology
This lecture is part of a special educational symposium exploring controversies in cardiovascular risk management and compared and contrasted best common practices and guidelines on both sides of the Atlantic. American and European experts discussed novel insights from basic and translational cardiovascular science in the context of ongoing and future clinical studies
The program is an initiative of research leaders from the Brigham and Women’s Hospital, Boston, USA in collaboration with the PACE foundation.
Samuel Z Goldhaber, MD – Director of Vascular Medicine & Director, Thrombosis Research Group Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Faculty did not receive an honorarium for their lectures